The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

por Dintsios, C. M., Beinhauer, I.
Publicado 2020

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee dis...

por Dintsios, C. M., Worm, F., Ruof, J., Herpers, M.
Publicado 2019

Direct costs in impaired glucose regulation: results from the population-based Heinz Nixdorf Recall study

por Bächle, C, Claessen, H, Andrich, S, Brüne, M, Dintsios, C M, Slomiany, U, Roggenbuck, U, Jöckel, K H, Moebus, S, Icks, A
Publicado 2016

Health care utilization and excess costs after pelvic fractures among older people in Germany

por Andrich, S., Haastert, B., Neuhaus, E., Frommholz, K., Arend, W., Ohmann, C., Grebe, J., Vogt, A., Brunoni, C., Jungbluth, P., Thelen, S., Dintsios, C.-M., Windolf, J., Icks, A.
Publicado 2021